Expansion of overseas operations, centered on Asia

「In September 2022, Alfresa Pharma Corporation opened a branch office in Shanghai, China, for its subsidiary and consolidated subsidiary, 青島耐絲克医材有限公司 (head office: Qingdao, Shandong Province, People's Republic of China). Using the Shanghai branch as a new operating base, the Company aims to expand its product offerings in China and grow its business there.」

「Expanding sales of diagnostic reagents and sutures in China, Europe and the United States, and expanding the Vietnam business」

「In the pharmaceutical and other manufacturing business, we are implementing the priority measures identified under the “19-21 Medium-Term Management Plan” to strengthen group synergies and achieve further scale: “Promoting safe, secure, and sincere manufacturing,” “Expanding products in line with group needs,” “Expanding contract manufacturing and the pharmaceutical API business,” and “Expanding overseas operations.”」

「In the pharmaceutical and other manufacturing business, we are implementing the priority measures identified under the “19-21 Medium-Term Management Plan” to strengthen group synergies and achieve further scale: “Promoting safe, secure, and sincere manufacturing,” “Expanding products in line with group needs,” “Expanding contract manufacturing and the pharmaceutical API business,” and “Expanding overseas operations.”」

「In March 2019, Alfresa Pharma Co., Ltd. entered into a supply agreement with 上海復星長征医学科学有限公司 (headquartered in Shanghai, China) for fecal testing equipment and reagent products in China. As part of its efforts to expand overseas operations, the company also entered into an agreement in March 2019 with 華潤医薬商業集団有限公司, a major Chinese pharmaceutical wholesaler, regarding a comprehensive strategic business alliance.」

「Alfresa Healthcare Co., Ltd., a consolidated subsidiary of the company (headquartered in Chuo-ku, Tokyo), opened a representative office in Taipei in November 2018 to support the promotional activities of its customers operating retail stores in Taiwan and to promote sales of its exclusive products and products from exclusive manufacturers.」

「In the pharmaceutical and other manufacturing business, we continue to implement the priority measures identified under the “16-18 Medium-Term Management Plan”: “Promoting safe, secure, and sincere manufacturing,” “Promoting contract manufacturing and the pharmaceutical API business,” “Expanding the product lineup and strengthening sales capabilities,” and “Expanding overseas operations.”」

「In the pharmaceutical and other manufacturing business, we continued to implement the segment-specific priority measures under the 16-18 Medium-Term Management Plan: “Promoting contract manufacturing and the active pharmaceutical ingredient business,” “Expanding the product lineup and strengthening sales capabilities,” and “Expanding overseas operations.”」

「In the pharmaceutical and other manufacturing business, we continued to implement the segment-specific priority measures under the 16-18 Medium-Term Management Plan: “Promoting contract manufacturing and the active pharmaceutical ingredient business,” “Expanding the product lineup and strengthening sales capabilities,” and “Expanding overseas operations.”」

「In the pharmaceutical and other manufacturing business, we continued to implement the segment-specific priority measures under the 16-18 Medium-Term Management Plan: “Promoting contract manufacturing and the active pharmaceutical ingredient business,” “Expanding the product lineup and strengthening sales capabilities,” and “Expanding overseas operations.”」

「Alfresa Pharma Co., Ltd., a consolidated subsidiary of the company (headquartered in Chuo-ku, Osaka), has a subsidiary, 青島耐絲克医材有限公司 (headquartered in Qingdao, Shandong Province, China), which completed a new plant building for medical devices compliant with international standards on its premises in November 2016. The company aims to expand sales in the growing Chinese market.」

「In addition, leveraging the know-how cultivated through our strong domestic business model, we will continue expanding our overseas business, mainly in Asia.」